Treatment

The ARSACS Foundation is now
working with pharmaceutical companies
to develop a treatment for ARSACS

Read more

Several research projects
are currently funded
by the Foundation
in Canada and abroad

Read more

The Ataxia gene can be
passed through many generations
without manifesting any symptoms

Read more

Corporations make a difference

Read more

We need your support
to continue our research
because research heals

Donate now

"Dîner des Producteurs"

annual fundraiser for ARSCAS research

Learn More

Latest News

Meeting
Jan 26, 2016 - Meeting of ARSACS researchers
There will be a meeting of all researchers working on ARSACS projects on April 13, 2016 in Montreal.
Meeting

Jan 12, 2016 - Research grants available to researchers

The Foundation continues to fund ARSACS research projects in 2016, a maximum of $100,000 per year with a possiblilty of renewal for a second year. If you are interested in the subject, please send your completed application form now. The deadline is May 20, 2016.

Read More

Meeting

Jan 03, 2016- $729,000 for ARSACS research

The "Dîner des Producteurs" held in Montreal on December 3 raised the net sum of $729,000 for ARSACS research. The Ataxia Charlevoix-Saguenay Foundation would like to thank the attendees and donors for their support and generosity

Read More

Meeting

Jan 02, 2016- Conference call with a pharmaceutical

A conference call with a pharmaceutical company is scheduled for January 12th to discuss the possibility of inserting a compound on ARSACS mice. More details to come.

Research

Dec 29, 2015- Care4Rare Year 2 Summary

Care4Rare is a research project to identify therapeutic leads for rare diseases such as ARSACS. The Foundation is financing the ARSACS portion under the leadership of Dr. Kym Boycott and Dr. Alex MacKenzie from the Children Hospital of Eastern Ontario. Year 2 Summary

Research

Dec 27, 2015- E-Rare-3 Call for Proposals

The Foundation is looking for researchers/partners interested in participating in the 2016 E-Rare-3 competition. The pre-registration deadline for proposals is February 1,2016. For more information please see E-Rare-3 Call for Proposals

News

Dec 23, 2015- Phase II chronic study on the ARSACS mouse not to be pursued

The phase II chronic study on the ARSACS mouse with respect to a compound is now at a wrap up stage. The conclusions of the study can be summarized by a problematic delivery of the compound. Therefore, the study will no be pursued further.